BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCTX BriaCell Therapeutics Corp.

Closed 03-25 16:00:00 EDT

4.09

-0.37

-8.30%

盘后4.10

+0.01+0.24%

19:37 EDT

High4.69	Low4.03	Vol58.25K
Open4.50	D1 Closing4.46	Amplitude14.76%
Mkt Cap15.17M	Tradable Cap10.21M	Total Shares3.71M
T/O249.70K	T/O Rate2.33%	Tradable Shares2.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"BCTX","market":"US","secType":"STK","nameCN":"BriaCell Therapeutics Corp.","latestPrice":4.09,"timestamp":1742932800000,"preClose":4.46,"halted":0,"volume":58245,"hourTrading":{"tag":"盘后","latestPrice":4.1,"preClose":4.09,"latestTime":"19:37 EDT","volume":313,"amount":1280.99,"timestamp":1742945841221},"delay":0,"floatShares":2497216,"shares":3709440,"eps":-13.019385,"marketStatus":"Closed","change":-0.37,"latestTime":"03-25 16:00:00 EDT","open":4.5,"high":4.69,"low":4.0317,"amount":249696.21598349998,"amplitude":0.147601,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-13.019385,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1742976000000},"marketStatusCode":5,"adr":0,"listingDate":1614142800000,"exchange":"NASDAQ","adjPreClose":4.46,"postHourTrading":{"tag":"盘后","latestPrice":4.1,"preClose":4.09,"latestTime":"19:37 EDT","volume":313,"amount":1280.99,"timestamp":1742945841221},"volumeRatio":1.192685,"impliedVol":0.6054,"impliedVolPercentile":0.1792},"requestUrl":"/m/hq/s/BCTX/wiki","defaultTab":"wiki","newsList":[{"id":"2520456049","title":"BriaCell Therapeutics Says Data Safety Monitoring Board Recommends Continuation of Phase 3 Trial in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520456049","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520456049?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:46","pubTimestamp":1742474760,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  announced Thursday that an external data safety monitoring board has completed its second safety data review and recommended that the company continue \"without any modifications\" its current pivotal phase 3 trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.The company added that it is currently conducting the phase 3 trial under the US Food and Drug Administration's fast-track designation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCTX","BK4139","LENZ"],"gpt_icon":0},{"id":"2520453728","title":"Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520453728","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520453728?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:00","pubTimestamp":1742472000,"startTime":"0","endTime":"0","summary":"The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT plus immune check point inhibitor in metastatic brea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046182/0/en/Second-Data-Safety-Monitoring-Board-Issues-Positive-Recommendation-to-Continue-BriaCell-s-Phase-3-Study-in-Metastatic-Breast-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPI","BK4139","BCTX"],"gpt_icon":0},{"id":"2520686218","title":"Briacell Therapeutics Corp reports results for the quarter ended January 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2520686218","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520686218?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 05:02","pubTimestamp":1742245323,"startTime":"0","endTime":"0","summary":"Briacell Therapeutics Corp reports results for the quarter ended January 31 - Earnings SummaryBriacell Therapeutics Corp BCT.TO reported a quarterly adjusted loss of $2.33 per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nL8N3Q01TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX"],"gpt_icon":0},{"id":"2519330889","title":"Briacell Therapeutics Corp  expected to post a loss of $1.12 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519330889","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519330889?lang=en_us&edition=full_marsco","pubTime":"2025-03-15 04:48","pubTimestamp":1741985286,"startTime":"0","endTime":"0","summary":"Briacell Therapeutics Corp  expected to post a loss of $1.12 a share - Earnings Preview Briacell Therapeutics Corp BCT.TO  is expected to show no change in quarterly revenue when it reports  results o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX25X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX"],"gpt_icon":0},{"id":"2514709113","title":"Wedbush Initiates BriaCell Therapeutics at Outperform With $15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514709113","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514709113?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:28","pubTimestamp":1740490089,"startTime":"0","endTime":"0","summary":"Wedbush Initiates BriaCell Therapeutics at Outperform With $15 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCTX","LENZ"],"gpt_icon":0},{"id":"2509226408","title":"BriaCell Announces Positive Shareholder Meeting Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2509226408","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509226408?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 09:02","pubTimestamp":1738803742,"startTime":"0","endTime":"0","summary":"An update from BriaCell Therapeutics ( ($TSE:BCT) ) is now available. BriaCell Therapeutics Corp. announced the successful outcomes of its annual g...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-announces-positive-shareholder-meeting-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-announces-positive-shareholder-meeting-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"gpt_icon":0},{"id":"2509635632","title":"BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2509635632","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509635632?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 07:15","pubTimestamp":1738797300,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb.  05, 2025  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biote","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3021661/0/en/BriaCell-Therapeutics-Corp-Announces-Results-of-Shareholder-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","BK4139"],"gpt_icon":0},{"id":"2509722254","title":"BriaCell Therapeutics Secures $3.05 Million in Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2509722254","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509722254?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 05:40","pubTimestamp":1738791608,"startTime":"0","endTime":"0","summary":"The latest update is out from BriaCell Therapeutics ( ($TSE:BCT) ). BriaCell Therapeutics has successfully closed its public offering, raising $3.0...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-secures-3-05-million-in-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-secures-3-05-million-in-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BCTX","BK4139"],"gpt_icon":0},{"id":"2509516882","title":"BriaCell Therapeutics Announces Closing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2509516882","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509516882?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 05:05","pubTimestamp":1738789500,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. The Company received gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, of $3.05 million. The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.ThinkEquity acted as sole placement agent for the offering.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-therapeutics-announces-closing-public-210500067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","BCTXW","BCTX"],"gpt_icon":0},{"id":"2509123098","title":"BRIACELL THERAP (BCTX) Upgraded to Buy: What Does It Mean for the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2509123098","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509123098?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 01:00","pubTimestamp":1738774812,"startTime":"0","endTime":"0","summary":"BRIACELL THERAP  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for BRIACELL THERAP basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-therap-bctx-upgraded-buy-170012297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTX","BCTXW"],"gpt_icon":0},{"id":"2508384171","title":"BriaCell Therapeutics Shares Hit Record Low After Public Offering News","url":"https://stock-news.laohu8.com/highlight/detail?id=2508384171","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508384171?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 06:27","pubTimestamp":1738621620,"startTime":"0","endTime":"0","summary":"Shares of BriaCell Therapeutics were trading at all-time lows in Monday's after-hours market, following news the company plans to sell shares in a best-efforts public offering.After the bell, shares were trading 22% lower at $3.90. Although the stock finished the day's regular session at $5.04, relatively flat, shares were at an all-time low of $4.66 during Monday's session.The biotechnology company said it will use proceeds from the offering primarily for working capital requirements, general corporate purposes, and the advancement of business objectives.BriaCell said it is developing novel immunotherapies to transform cancer care.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BCTX","BK4139"],"gpt_icon":0},{"id":"2508176045","title":"BriaCell Therapeutics Announces Public Offering to Fuel Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2508176045","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508176045?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 06:07","pubTimestamp":1738620478,"startTime":"0","endTime":"0","summary":"An update from BriaCell Therapeutics ( ($TSE:BCT) ) is now available. BriaCell Therapeutics announced a proposed public offering of common shares, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-announces-public-offering-to-fuel-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-announces-public-offering-to-fuel-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2508763661","title":"BriaCell announces common stock offering, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2508763661","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508763661?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 05:50","pubTimestamp":1738619411,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) Therapeutics announced that it intends to offer to sell common shares in a best-efforts public offering. ThinkEquity is acting as s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-announces-common-stock-offering-no-amount-given?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-announces-common-stock-offering-no-amount-given?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","BK4139"],"gpt_icon":0},{"id":"2508175088","title":"BriaCell Therapeutics Announces Proposed Public Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175088?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 05:45","pubTimestamp":1738619100,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Feb.  03, 2025  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/03/3019898/0/en/BriaCell-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BCTX"],"gpt_icon":0},{"id":"2508314039","title":"Promising Results and Strategic Expansion Underpin Buy Rating for BriaCell Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2508314039","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508314039?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 23:55","pubTimestamp":1738598116,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on BriaCell Therapeutics (BCT – Research Report), boosting the price target to $32....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/uncategorized/promising-results-and-strategic-expansion-underpin-buy-rating-for-briacell-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/uncategorized/promising-results-and-strategic-expansion-underpin-buy-rating-for-briacell-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","LENZ"],"gpt_icon":0},{"id":"2508144642","title":"BriaCell Therapeutics trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508144642?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 22:45","pubTimestamp":1738593921,"startTime":"0","endTime":"0","summary":"09:41 EST BriaCell (BCTX) Therapeutics trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-therapeutics-trading-resumes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-therapeutics-trading-resumes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BCTX"],"gpt_icon":0},{"id":"2508011705","title":"BriaCell announces resolution of lung metastasis in patient receiving Bria-OTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2508011705","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508011705?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 20:41","pubTimestamp":1738586470,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) Therapeutics announces an unprecedented clinical response including resolution of a lung metastasis with stable disease elsewhere. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-announces-resolution-of-lung-metastasis-in-patient-receiving-bria-ots?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-announces-resolution-of-lung-metastasis-in-patient-receiving-bria-ots?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","BK4139"],"gpt_icon":0},{"id":"2508111791","title":"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™","url":"https://stock-news.laohu8.com/highlight/detail?id=2508111791","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508111791?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 20:30","pubTimestamp":1738585800,"startTime":"0","endTime":"0","summary":"Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS monotherapyNo toxicity related to the treatment; Patient remains on studyUnprecedent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/03/3019425/0/en/BriaCell-Announces-Resolution-of-Lung-Metastasis-in-First-Patient-treated-with-Bria-OTS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","MBC","BK4086","BK4139"],"gpt_icon":0},{"id":"2506532711","title":"BriaCell Completes 15:1 Share Consolidation for Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2506532711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506532711?lang=en_us&edition=full_marsco","pubTime":"2025-01-28 08:38","pubTimestamp":1738024690,"startTime":"0","endTime":"0","summary":"The latest announcement is out from BriaCell Therapeutics ( ($TSE:BCT) ). BriaCell Therapeutics Corp. announced the completion of a 15:1 share cons...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-completes-151-share-consolidation-for-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-completes-151-share-consolidation-for-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIW.SI","BK4588","TQQQ","NDAQ","USAW.SI","IE00BGHQF748.EUR","LU2095319765.USD","LU2210149790.SGD","QID","QLD","USJW.SI","BK4585",".IXIC","MNQmain","BK4139","BCTX","NQmain","IE00BKPKM429.USD","PSQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4112","TSYW.SI","SQQQ"],"gpt_icon":0},{"id":"2506311115","title":"BriaCell Announces Completion of 15:1 Share Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2506311115","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506311115?lang=en_us&edition=full_marsco","pubTime":"2025-01-28 07:42","pubTimestamp":1738021320,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Jan.  27, 2025  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechno","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/27/3016038/0/en/BriaCell-Announces-Completion-of-15-1-Share-Consolidation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","TQQQ","MNQmain","USJW.SI","BCTX","BK4139","SQQQ","QID","TSYW.SI",".IXIC","NQmain","USAW.SI","QLD","NVIW.SI"],"gpt_icon":1}],"profile":{"websiteUrl":"http://briacell.com","stockEarnings":[{"period":"1week","weight":0.0958},{"period":"1month","weight":0.009},{"period":"3month","weight":-0.4462},{"period":"6month","weight":-0.6088},{"period":"1year","weight":-0.882},{"period":"ytd","weight":-0.4737}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":-0.0431},{"period":"3month","weight":-0.0453},{"period":"6month","weight":0.0071},{"period":"1year","weight":0.1014},{"period":"ytd","weight":-0.0205}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.05711},{"month":2,"riseRate":0.25,"avgChangeRate":-0.068829},{"month":3,"riseRate":0.8,"avgChangeRate":0.111674},{"month":4,"riseRate":0,"avgChangeRate":-0.150063},{"month":5,"riseRate":0,"avgChangeRate":-0.204537},{"month":6,"riseRate":0.75,"avgChangeRate":0.134713},{"month":7,"riseRate":0.5,"avgChangeRate":-0.054561},{"month":8,"riseRate":1,"avgChangeRate":0.163345},{"month":9,"riseRate":0.5,"avgChangeRate":0.089973},{"month":10,"riseRate":0,"avgChangeRate":-0.176016},{"month":11,"riseRate":0.75,"avgChangeRate":0.166718},{"month":12,"riseRate":0.25,"avgChangeRate":-0.165944}],"exchange":"NASDAQ","name":"BriaCell Therapeutics Corp.","nameEN":"BriaCell Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BriaCell Therapeutics Corp.,BCTX,BriaCell Therapeutics Corp.股票,BriaCell Therapeutics Corp.股票老虎,BriaCell Therapeutics Corp.股票老虎国际,BriaCell Therapeutics Corp.行情,BriaCell Therapeutics Corp.股票行情,BriaCell Therapeutics Corp.股价,BriaCell Therapeutics Corp.股市,BriaCell Therapeutics Corp.股票价格,BriaCell Therapeutics Corp.股票交易,BriaCell Therapeutics Corp.股票购买,BriaCell Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction